A Second-Generation BTK Inhibitor for Chronic Lymphocytic Leukemia

The B-cell receptor signaling pathway is integral to the pathogenesis of most B-cell malignancies, including chronic lymphocytic leukemia (CLL). One potential target in that pathway is Bruton tyrosine kinase (BTK). Acalabrutinib (ACP-196), an irreversible BTK inhibitor, lacks much of the “off-target” binding of the first-in-class agent, ibrutinib. Investigators conducted a manufacturer-funded, uncontrolled trial of …